Latest China Expansion News

Australian Dairy Nutritionals reported a 54% year-on-year revenue fall in the September quarter and held just A$513,000 in cash against a A$619,000 operating cash outflow. The infant formula group is pursuing a A$500,000 placement and a broader capital raise as it waits for China distribution growth and Vietnam sales to rebuild momentum.

Merino & Co cut its FY2026 loss by 20% as China revenue more than doubled, but group revenue declined and cash reserves fell sharply. The auditor highlighted a material uncertainty over the company’s ability to continue as a going concern.

Cettire returned to positive operating cash flow in FY26, but its annual report carries a material uncertainty over going concern after current liabilities exceeded current assets by A$51.8 million. The luxury e-commerce group also posted an A$8.5 million statutory loss and is relying on working-capital discipline, VAT recoveries and potentially conditional director support.

CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.

CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

Kingfish Limited’s portfolio endured a tough first quarter of 2026, with a 7.2% adjusted NAV decline amid Iran conflict-driven volatility. While a2 Milk’s expansion in China buoyed gains, shares in consumer-exposed names and tech-linked Vista Group plunged sharply.

Australian Dairy Nutritionals Group has cut its net loss by 40% in the half-year to December 2025, driven by a remarkable 431% revenue jump in its nutritional powders segment amid expanding Chinese distribution.

CurveBeam AI has received the first A$4 million tranche of a planned A$10 million strategic investment from a leading Chinese orthopaedic device company, marking a significant step in its expansion into the Chinese market.

Appen Limited delivered a robust Q4 FY25, driven by explosive growth in its China segment and strong gains in generative AI projects globally, boosting revenue and profitability significantly.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.